BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: a meta-analysis.

摘要: Epidemiologic studies have evaluated the association between BRAF mutations and resistance to treatment of anti-EGFR monoclonal antibodies (MoAb) in patients with metastatic colorectal cancer (mCRC). However, results are still inconclusive. To derive a more precise estimation relationship, we performed this meta-analysis. A total 11 were included final There seven for unselected mCRC four wild type KRAS mCRC. Among patients, V600E mutation was detected 48 546 primary tumors (8.8%). The objective response rate (ORR) mutant 29.2% (14/48), whereas ORR wild-type 33.5% (158/472).The overall RR over 0.86 (95% CI = 0.57–1.30; P 0.48). For mCRC, 40 376 (10.6%). 0.0% (0/40), 36.3% (122/336). pooled 0.14 0.04–0.53; 0.004). In conclusion, meta-analysis provides evidence that is associated lack treated MoAbs. may be used as an additional biomarker selection who might benefit from MoAbs therapy.